Kirsten L. Bryant

This study identifies Survivin as a critical KRAS signaling partner that promotes glycolytic activity in PDAC cells by forming microtubule-based complexes with glycolytic enzymes.

This study identifies folate receptor beta (FRβ) as a metabolic checkpoint on tumor-associated macrophages (TAMs) that promotes immunosuppression and tumor growth.

This study shows that combining AXL inhibition with RAS or ERK inhibitors enhances efficacy in KRAS-mutant cancers by overcoming resistance mechanisms.

This study identifies that vertical inhibition of the autophagy pathway enhances sensitivity to mTORC1 inhibition in PDAC, improving therapeutic efficacy.

This study identifies KEAP1 loss as a resistance mechanism to KRAS inhibitors in pancreatic and lung cancer and shows that combining glutamine inhibition with KRAS inhibitors can overcome this resistance.

This study shows that ONC201 inhibits KRAS-mutant pancreatic cancer growth and overcomes resistance to RAS inhibitors by activating ClpP and altering metabolic pathways.